Dealroom – TechBio & Drug Discovery, 2024

In the report by the Dealroom – TechBio & Drug Discovery report for 2024, highlighted that there is a correlation between the amount of funding received and the cost of drug development per phase, with a negative relationship being observed. The majority of investment is directed towards the initial phases of the discovery pipeline, with the expectation that new AI and computational platforms will enhance clinical success rates. The ultimate goal is to develop drugs that are derived from computational and AI technologies, which would have a higher likelihood of clinical success. This indicates a shift towards utilizing technology to drive advancements in the field of drug discovery and development.